References:
1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med . Feb 1 2018;378(5):439-448. doi:10.1056/NEJMoa1709866
2. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. N Engl J Med . Jan 21 2021;384(3):252-260. doi:10.1056/NEJMoa2031054
3. Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene Autotemcel Gene Therapy for Non-beta(0)/beta(0) Genotype beta-Thalassemia. N Engl J Med . Feb 3 2022;386(5):415-427. doi:10.1056/NEJMoa2113206
4. Pulsipher MA, Langholz B, Wall DA, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood . Mar 27 2014;123(13):2017-25. doi:10.1182/blood-2013-10-534297
5. Pulsipher MA, Langholz B, Wall DA, et al. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplant . Sep 2015;50(9):1173-9. doi:10.1038/bmt.2015.103
6. Bader P, Salzmann-Manrique E, Balduzzi A, et al. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv . Nov 12 2019;3(21):3393-3405. doi:10.1182/bloodadvances.2019000449
7. Pulsipher MA, Carlson C, Langholz B, et al. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood . May 28 2015;125(22):3501-8. doi:10.1182/blood-2014-12-615757
8. Peters C, Dalle JH, Locatelli F, et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol . Feb 1 2021;39(4):295-307. doi:10.1200/JCO.20.02529
9. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant . Sep 2003;32(6):543-8. doi:10.1038/sj.bmt.1704198
10. Gupta V, Braun TM, Chowdhury M, Tewari M, Choi SW. A Systematic Review of Machine Learning Techniques in Hematopoietic Stem Cell Transplantation (HSCT). Sensors (Basel) . Oct 27 2020;20(21)doi:10.3390/s20216100
11. Locatelli F, Crotta A, Ruggeri A, et al. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood . Sep 19 2013;122(12):2135-41. doi:10.1182/blood-2013-03-491589
12. Yabe M, Ohtsuka Y, Watanabe K, et al. Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan. Int J Hematol . Feb 2015;101(2):184-90. doi:10.1007/s12185-014-1715-7
13. Dvorak CC, Satwani P, Stieglitz E, et al. Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children’s Oncology Group study. Pediatr Blood Cancer . Jul 2018;65(7):e27034. doi:10.1002/pbc.27034
14. Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood . Nov 15 2008;112(10):4318-27. doi:10.1182/blood-2007-06-098020
15. Cornetta K, Laughlin M, Carter S, et al. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). Biol Blood Marrow Transplant . Feb 2005;11(2):149-60. doi:10.1016/j.bbmt.2004.11.020
16. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.Blood . Oct 15 2007;110(8):3064-70. doi:10.1182/blood-2007-04-067215
17. Wagner JE, Jr., Eapen M, Carter S, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med . Oct 30 2014;371(18):1685-94. doi:10.1056/NEJMoa1405584
18. Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol . Sep 2013;14(10):999-1008. doi:10.1016/S1470-2045(13)70309-7
19. Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1.Bone Marrow Transplant . Jul 2013;48(7):947-52. doi:10.1038/bmt.2012.276
20. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol . Jul 2000;18(13):2567-75. doi:10.1200/JCO.2000.18.13.2567
21. Park JR, Kreissman SG, London WB, et al. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.JAMA . Aug 27 2019;322(8):746-755. doi:10.1001/jama.2019.11642
22. Ladenstein R, Potschger U, Pearson ADJ, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.Lancet Oncol . Apr 2017;18(4):500-514. doi:10.1016/S1470-2045(17)30070-0
23. Granger MM, Naranjo A, Bagatell R, et al. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children’s Oncology Group Trial ANBL12P1. Transplant Cell Ther . Jun 2021;27(6):490 e1-490 e8. doi:10.1016/j.jtct.2021.03.006
24. Reddy AT, Strother DR, Judkins AR, et al. Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children’s Oncology Group Trial ACNS0333. J Clin Oncol . Apr 10 2020;38(11):1175-1185. doi:10.1200/JCO.19.01776
25. Rare Tumors in Kids May Respond to Tazemetostat. Cancer Discov . Jan 2018;8(1):OF5. doi:10.1158/2159-8290.CD-NB2017-152
26. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science . Mar 15 2002;295(5562):2097-100. doi:10.1126/science.1068440
27. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood . Jun 15 2005;105(12):4878-84. doi:10.1182/blood-2004-12-4825
28. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood . Nov 15 2002;100(10):3825-7. doi:10.1182/blood-2002-04-1197
29. Horan JT, Alonzo TA, Lyman GH, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children’s Oncology Group. J Clin Oncol . Dec 10 2008;26(35):5797-801. doi:10.1200/JCO.2007.13.5244
30. Masetti R, Muratore E, Gori D, Prete A, Locatelli F. Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis. Ann Hematol . Nov 2022;101(11):2497-2506. doi:10.1007/s00277-022-04965-x
31. Pollard JA, Alonzo TA, Gerbing R, et al. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children’s Oncology Group Protocol AAML1031. J Clin Oncol . Jun 20 2022;40(18):2023-2035. doi:10.1200/JCO.21.01612
32. Brown PA, Ji L, Xu X, et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA . Mar 2 2021;325(9):833-842. doi:10.1001/jama.2021.0669
33. Alexander S, Fisher BT, Gaur AH, et al. Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.JAMA . Sep 11 2018;320(10):995-1004. doi:10.1001/jama.2018.12512
34. Dvorak CC, Fisher BT, Esbenshade AJ, et al. A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant. J Pediatric Infect Dis Soc . Apr 30 2021;10(4):417-425. doi:10.1093/jpids/piaa119
35. Otto WR, Dvorak CC, Boge CLK, et al. Prospective Evaluation of the Fungitell(R) (1–>3) Beta-D-Glucan Assay as a Diagnostic Tool for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplantation: A Report from the Children’s Oncology Group.Pediatr Transplant . Feb 2023;27(1):e14399. doi:10.1111/petr.14399
36. Andolina JR, Wang YC, Ji L, et al. Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children’s Oncology Group experience.Bone Marrow Transplant . Mar 2022;57(3):445-452. doi:10.1038/s41409-021-01558-6
37. Qayed M, Wang T, Hemmer MT, et al. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.Biol Blood Marrow Transplant . Mar 2018;24(3):521-528. doi:10.1016/j.bbmt.2017.11.004
38. Nguyen CL, Docampo MD, van den Brink MR, Markey KA. The role of the intestinal microbiota in allogeneic HCT: clinical associations and preclinical mechanisms. Curr Opin Genet Dev . Feb 2021;66:25-35. doi:10.1016/j.gde.2020.11.007
39. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med . Oct 16 2014;371(16):1507-17. doi:10.1056/NEJMoa1407222
40. Schultz LM, Baggott C, Prabhu S, et al. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol . Mar 20 2022;40(9):945-955. doi:10.1200/JCO.20.03585
41. Symons HJ, Zahurak M, Cao Y, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv . Aug 25 2020;4(16):3913-3925. doi:10.1182/bloodadvances.2020001648
42. Merli P, Pagliara D, Mina T, et al. alphabetaT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes. Haematologica . Dec 1 2022;107(12):2966-2971. doi:10.3324/haematol.2022.280698
43. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med . Jul 24 2014;371(4):339-48. doi:10.1056/NEJMsa1311707
44. Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood . May 19 2016;127(20):2427-38. doi:10.1182/blood-2015-11-679639
45. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med . Dec 21 2017;377(25):2433-2444. doi:10.1056/NEJMoa1706640
46. Whangbo JS, Kim HT, Mirkovic N, et al. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv . Sep 10 2019;3(17):2550-2561. doi:10.1182/bloodadvances.2019000631
47. Koreth J, Kim HT, Jones KT, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood . Jul 7 2016;128(1):130-7. doi:10.1182/blood-2016-02-702852
48. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med . Dec 1 2011;365(22):2055-66. doi:10.1056/NEJMoa1108188
49. Aljebab F, Choonara I, Conroy S. Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children. PLoS One . 2017;12(1):e0170259. doi:10.1371/journal.pone.0170259
50. Etra A, Capellini A, Alousi A, et al. Effective treatment of low-risk acute GVHD with itacitinib monotherapy. Blood . Feb 2 2023;141(5):481-489. doi:10.1182/blood.2022017442
51. Motta CM, Keller MD, Bollard CM. Applications of virus-specific T cell therapies post-BMT. Semin Hematol . Jan 2023;60(1):10-19. doi:10.1053/j.seminhematol.2022.12.002
52. Hont AB, Cruz CR, Ulrey R, et al. Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study. J Clin Oncol . Sep 10 2019;37(26):2349-2359. doi:10.1200/JCO.19.00177
53. Elmas E, Saljoughian N, de Souza Fernandes Pereira M, et al. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.Front Oncol . 2022;12:834002. doi:10.3389/fonc.2022.834002
54. Kinoshita H, Cooke KR, Grant M, et al. Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Adv . Apr 26 2022;6(8):2520-2534. doi:10.1182/bloodadvances.2021006831
55. Naik S, Vasileiou S, Tzannou I, et al. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL. Blood . Apr 28 2022;139(17):2706-2711. doi:10.1182/blood.2021014648
56. Shalabi H, Qin H, Su A, et al. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood . Aug 4 2022;140(5):451-463. doi:10.1182/blood.2022015795
57. Yanik GA, Mineishi S, Levine JE, et al. Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant . Jul 2012;18(7):1044-54. doi:10.1016/j.bbmt.2011.11.031
58. Schofield HT, Fabrizio VA, Braniecki S, et al. Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task Force. Transplant Cell Ther . Oct 2022;28(10):625-636. doi:10.1016/j.jtct.2022.06.027
59. Zerr DM, Milstone AM, Dvorak CC, et al. Chlorhexidine gluconate bathing in children with cancer or those undergoing hematopoietic stem cell transplantation: A double-blinded randomized controlled trial from the Children’s Oncology Group. Cancer . Jan 1 2021;127(1):56-66. doi:10.1002/cncr.33271
Figure 1 : The collaborative network of the Cellular Therapy Committee of the Children’s Oncology Group. Abbreviations: ALL – Acute lymphoblastic leukemia, AML – Acute myelogenous leukemia, NB – neuroblastoma, CNS – Central nervous system, CCL – Cancer Control, AYA – Adolescent and young adult, PTCTC – Pediatric Transplant and Cellular Therapy Consortium, BMT CTN – Bone marrow transplant clinical trials network.
Figure 2 : Intricate logistics involved in delivery of novel cellular therapy, including potential patient barriers. Adapted from ASTCT-NMDP ACCESS Initiative presentation, provided by Jeffrey Auletta.
Figure 1: